Join Swanson Reed, UHY Haines Norton and Wrays for a practical workshop that will focus on the problems that every day companies face in protecting, and claiming incentives for their new products.
You will hear from three industry experts on a range of topics, including tax issues, R&D tax incentives and patent protection.
On conclusion of the presentation, participants will have an opportunity to ask the panel any specific questions in a friendly and constructive forum.
Time | Presentation | Presenter | |
7:00am – 7:30am: | Session 1: Protecting Intellectual Property (IP) | Joe Seisdedos | |
7:30am – 8:00am: | Session 2: IP & Relevant Tax Considerations | Bill Charlton | |
8:00am – 8:30am: | Session 3: R&D Tax Incentives | Michael Oon | |
8:30am – 9:00am: | Session 4: Panel Q&A and Networking Opportunity |
Joe Seisdedos | Bill Charlton | Michael Oon |
![]() |
![]() |
![]() |
View Joe’s bio | View Bill’s bio | View Michael’s bio |
Wednesday, 18th June 2014
7am – 9am
Swanson Reed Boardroom
Level 11, 42-60 Albert St
Brisbane, 4000
Cost: Free!
Register Before: Friday 13th June
Full attendance at this workshop will yield 2 CPE hours towards the Tax Practitioners Board’s (TPB) CPE requirements.
Contact Amy Nolan for more information:
Ph: 07 3221 1499
Mob: 0435 713 493
Are you Eligible to claim R&D? Take our R&D Eligibility Survey and find out.
Swanson Reed presenting R&D Tax update at MSIA Event – July 2024
Swanson reed is providing an update on the R&D Tax Incentive at an event on Thursday, July 25th, 2024 in Brisbane presented by MSIA (Medical Software Industry Association). The 2024 MSIA Brisbane event is being held in conjunction with the Australian Digital Health Agency (ADHA) to provide a full day of updates and insights in Digital Health. Swanson Reed’s update will provide an update on R&D Tax including insight into current policy discussions leading into the upcoming review of Australia’s […]
Significant Refundable R&D Offsets receipts reported to the ASX in recent months
Over recent months, a number of companies have reported to the ASX receipt of substantial Refundable R&D Tax Offsets. Notable receipts include: Recce Pharmaceuticals (ASX: RCE) received $2.6 M related to its anti-infective platform; Latrobe Magnesium (ASX: LMG) received $12.5 M related to Magnesium extraction technology; Group 6 Metals (ASX:G6M) received $14.3 M related to processes for producing higher value tungsten products Orthocell Limited (ASX: SNT) received $3.05 M related to its mobility regeneration technology; Botanix (ASX: BOT) received $3 […]